Prostate Specific Antigen (PSA) Test Global Market Report 2024

The prostate specific antigen (psa) test market size has grown rapidly in recent years. It will grow from $3.66 billion in 2023 to $4.13 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%. The growth observed in the historical period can be attributed to factors such as increased awareness, an aging population, advancements in medical technology, clinical recommendations, and progress in pharmaceutical developments.

The prostate specific antigen (psa) test market size is expected to see rapid growth in the next few years. It will grow to $6.4 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The anticipated growth in the forecast period can be attributed to advancements in test accuracy, the adoption of a personalized medicine approach, and the impact of a globally aging population. Significant trends expected in the forecast period include a shift towards biomarker combinations, technological innovations, the integration of point-of-care testing, the incorporation of digital health solutions, and a heightened focus on early detection and prevention.

The projected expansion of the prostate-specific antigen (PSA) test market is fueled by the increasing incidence of prostate cancer. Prostate cancer, affecting the prostate gland in the male reproductive system, is a condition that warrants early detection and risk assessment. The PSA test serves as a prevalent screening tool for prostate cancer, measuring PSA levels in the bloodstream. Recent reports from the American Society of Clinical Oncology (ASCO) in March 2023 revealed that in the United States alone, an estimated 288,300 men were diagnosed with prostate cancer, with approximately 34,700 succumbing to the disease in 2023. Globally, it is anticipated that around 1,414,259 individuals will be diagnosed with prostate cancer in 2020. Consequently, the escalating prevalence of prostate cancer is a driving force behind the growth of the PSA test market.

The upswing in chronic diseases contributes to the burgeoning demand for PSA tests. Chronic diseases, characterized by prolonged medical conditions necessitating ongoing attention and management, include prostate cancer as one such condition. The PSA test emerges as a pivotal tool for screening, diagnosis, and monitoring the progression of prostate cancer. Predictions from the National Library of Medicine in 2022 anticipate a 99.5% rise in the number of individuals aged 50 and older with at least one chronic illness, reaching 142.66 million by 2050. Furthermore, the prevalence of multimorbidity is projected to increase by 91.16%, encompassing 14.968 million people in 2050. Hence, the upsurge in chronic diseases is poised to propel the PSA test market.

A prominent trend in the PSA test market is the integration of technological advancements. Key players in the market are actively developing advanced screening tools to maintain their competitive edge. LynxDx Inc., a US-based diagnostic company, exemplifies this trend with the launch of MyProstateScore 2.0 in February 2023. This non-invasive urine prostate cancer screening test employs 18 biomarkers, including the innovative gene fusion T2,ERG, for personalized risk assessment. MyProstateScore 2.0 not only delivers highly accurate, stratified risk assessment insights but also guides clinical decisions for patients exhibiting elevated PSA or abnormal digital rectal exam (DRE) findings.

Major companies in the PSA test market are focusing on product development and launches, such as home testing kits for PSA. Home testing kits, facilitating self-administered diagnostic procedures, offer convenience and accessibility. In September 2023, Randox, an Ireland-based health and toxicology company, unveiled an at-home testing kit for PSA. This kit enables individuals to measure PSA levels in their blood, providing indications of abnormalities within the prostate. Elevated PSA levels may signal various conditions, including an enlarged prostate, prostatitis, urinary tract infection, or the potential presence of prostate cancer.

In June 2021., Bayer AG, a Germany-based pharmaceutical and biotechnology company, acquired Noria Therapeutics Inc. and PSMA Therapeutics Inc. This acquisition aims to broaden Bayer's portfolio of targeted alpha therapies (TATs) for prostate cancer, gain access to Noria's non-invasive urine test, and fortify its position in the prostate cancer market. PSMA Therapeutics Inc., a subsidiary of Noria Therapeutics Inc., specializes in providing PSA test services for prostate cancer.

Major companies operating in the prostate specific antigen (psa) test market report are Siemens AG, F. Hoffmann-La Roche AG, Bayer AG, Abbott Laboratories, Becton Dickinson and Company, PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Ortho-Clinical Diagnostics Inc., DiaSorin SpA, OPKO Health Inc., R&D Systems Inc., Meso Scale Diagnostics LLC, Tosoh America Inc., Fujirebio Europe N.V., Boditech Med Inc., DRG International Inc., BioVision Inc., Enzo Life Sciences Inc., RayBiotech Inc., Novus Biologicals LLC, Creative Diagnostics Inc., Elabscience, LifeSpan BioSciences Inc., American Laboratory Products Company Ltd., Accuquik Inc., AOBIOUS Inc., Boster Biological Technology Co. Ltd., Cell Biolabs Inc., Lomina AG.

North America was the largest region in the prostate specific antigen (PSA) test market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate specific antigen (psa) test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prostate specific antigen (psa) test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The main types of PSA tests include clinical laboratory improvement amendments (CLIA), enzyme-linked immunosorbent assay (ELISA), fluorescence immunoassay (FIA), and others. Clinical laboratory improvement amendments (CLIA) comprise a set of regulations governing laboratory testing, requiring clinical laboratories to obtain certification from the Centers for Medicare & Medicaid Services (CMS) before conducting diagnostic testing on human samples. These tests find applications in various areas, including screening and post-treatment monitoring, and are utilized by diverse end-users such as hospitals, diagnostic centers, research institutes, and others.

The prostate-specific antigen (PSA) test market research report is one of a series of new reports that provides prostate-specific antigen (PSA) test market statistics, including prostate-specific antigen (PSA) test industry global market size, regional shares, competitors with a prostate-specific antigen (PSA) test market share, detailed prostate-specific antigen (PSA) test market segments, market trends and opportunities, and any further data you may need to thrive in the prostate-specific antigen (PSA) test industry. This prostate-specific antigen (PSA) test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The prostate-specific antigen (PSA) test market includes revenues earned by entities by providing services such as prostate cancer detection, monitoring, PSA screening, prostatitis evaluation, complex PSA tests, and blood tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.